MDMA for Suicidality

8 papers and 0 clinical trials exploring mdma as a treatment for suicidality.

Compoundempathogen

MDMA

MDMA is a synthetic empathogen that enhances monoamine release, producing prosocial and anxiolytic effects without frank hallucinosis. Two Phase III trials demonstrated significant PTSD symptom reductions, though FDA review raised concerns about blinding, durability, and safety characterisation.

Full MDMA profile
Indication700,000 deaths annually worldwide.

Suicidality

Suicidality encompasses a spectrum of suicidal thoughts and behaviours, significantly impacting individuals globally. Recent research into psychedelics, particularly ketamine and ayahuasca, shows promise in rapidly alleviating suicidal ideation associated with mental health disorders.

Full Suicidality profile

Academic Research

8 papers
Open Accessindividual

The conceptual framework for the therapeutic approach used in phase 3 trials of MDMA-assisted therapy for PTSD

This paper articulates the conceptual framework behind the inner‑directed, relational and trauma‑informed psychotherapeutic approach used in Phase 3 MDMA‑assisted therapy trials for PTSD, centring the participant’s "inner healing intelligence", a non‑pathologising stance, therapist attunement, and integration of top‑down and bottom‑up processes. It notes that MDMA plus therapy outperformed placebo plus therapy on symptom reduction, while substantial improvement in control groups underscores the psychotherapy model’s independent efficacy and the need to identify which elements drive clinical benefit.

Published
Journal
Frontiers in Psychology
Authors
Alpert, M., Mithoefer, A. T., Mithoefer, M. C., Nicholas, C. R., O'Donnell, K., Okano, L., Ot’alora G, M., Poulter, B., Thomas, C.
Open Accessindividual

MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study

In a randomized, double‑blind, placebo‑controlled phase 3 trial of 90 patients with severe PTSD (including common comorbidities), MDMA‑assisted therapy produced a large, significant reduction in PTSD symptoms versus placebo (mean CAPS‑5 change −24.4 vs −13.9; P<0.0001, d=0.91) and improved functioning (SDS: P=0.0116, d=0.43). Treatment was well tolerated with no signals of abuse potential, increased suicidality or QT prolongation, indicating MDMA‑assisted therapy is a promising intervention warranting expedited evaluation.

Published
Journal
Nature Medicine
Authors
Amar, S., Amiaz, R., Bogenschutz, M. P., Brown, R., Carlin, S. C., Coker, A., de Boer, A., Doblin, R., Emerson, A., Garas, W., Gelfand, Y., Gorman, I., Hamilton, S., Hapke, E., Harrison, C., Klaire, S. S., Kleiman, S., Lilienstein, A., Marta, C. J., Matthews, R., Mitchell, J., Mithoefer, A. T., Mithoefer, M. C., Nicholas, C. R., Ot’alora G, M., Paleos, C., Parker-Guilbert, K., Poulter, B., Quevedo, S., Shannon, S., Tzarfaty, K., van der Kolk, B., Wallach, Y., Wang, J. B., Wells, G., Woolley, J. D., Worthy, R., Yazar-Klosinski, B.

Clinical Trials

0 trials

No clinical trials have been tagged with both MDMA and Suicidality yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all MDMA papers Search all Suicidality trials Full MDMA profile Full Suicidality profile